Denosumab + Placebo for risendronate + Risendronate + Placebo for denosumab
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Conditions
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Trial Timeline
Mar 28, 2012 → Jun 29, 2017
NCT ID
NCT01575873About Denosumab + Placebo for risendronate + Risendronate + Placebo for denosumab
Denosumab + Placebo for risendronate + Risendronate + Placebo for denosumab is a phase 3 stage product being developed by Amgen for Steroid-induced Osteopor, Glucocorticoid-induced Ostepor. The current trial status is completed. This product is registered under clinical trial identifier NCT01575873. Target conditions include Steroid-induced Osteopor, Glucocorticoid-induced Ostepor.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01575873 | Phase 3 | Completed |
Competing Products
1 competing product in Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dapagliflozin + Sliding scale insulin | AstraZeneca | Approved | 85 |